Ethanol solvate of (-)-cis-2-(2-chloropheny)-5,7-dihydroxy-8-[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1benzopyran-4-one

ABSTRACT

An ethanol solvate form of (−)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8-[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-one hydrochloride (Form II), a method of making Form II and a composition comprising Form II.

This application is a continuation of U.S. patent application Ser. No.09/760,590, filed Jan. 16, 2001, which claims the benefit of U.S.Provisional Application No. 60/287,593, filed Jan. 18, 2000, allincorporated herein by reference.

BACKGROUND OF THE INVENTION

1. Field of Invention

The present invention is directed toward an ethanol solvate form of(−)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8-[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-onehydrochloride (Form II), a method of making Form II, a pharmaceuticalcomposition comprising Form II and methods of using said Form II.

2. Description of the Art

The compound(−)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8-[4R-(3S-hydroxyl-1-methyl)piperidinyl]-4H-1-benzopyran-4-oneor one of its pharmaceutically acceptable salt forms (known as“Flavopiridol”) is an immunomodulator and antiinflammatory agent (U.S.Pat. No. 4,900,727), and inhibitor of oncogene-encoded kinases or growthfactor receptor tyrosine kinases (U.S. Pat. No. 5,284,856). Flavopiridolis a strong inhibitor of cyclin dependent kinases (CDKs) including CDK1,CDK2, CDK4, CDK6 and CDK7, (cdk1/cyclin B; cdk2/cyclin A; cdk2/cyclin E;cdk4/cyclinD; cdk6/cyclin D; cdk7/cyclin H) with the potential to causeinhibition of cell cycle progression in G₁ and G₂ by multiple mechanismsrelatable to cdk inhibition. See International Journal of Oncology 9:1143-1168 (1996). Also, Flavopiridol has been shown to inhibit the EGFreceptor family, the receptor associated SRC family kinases, and signaltransducing kinases. In vitro and in vivo experiments have shown thatFlavopiridol is able to inhibit a broad type range of human tumors,leukemias and lymphomas.

(−)-cis-2-(2-Chlorophenyl)-5,7-dihydroxy-8-[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-oneor a pharmaceutically acceptable salt thereof crystallizes into numeroussolvates with solvents such as ethanol, DMSO, methanol,acetonitrile/isopropanol, ethanolaisopropanol, and isopropanol andsolvate hydrates such as ethanol/ and isopropanolfwater combinations.The superior solvate form is the Flavopiridol hydrochloride ethanolsolvate form (hereafter “Form II”).

The use of ethanol over the other solvents used to produce solvatespresents advantages of less toxicity (e.g., methanol, isopropanolsolvates).

A subject of the instant invention is Form II of(−)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8-[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-one,this means the solvate of ethanol with(−)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8-[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-onehydrochloride. Said Form II can be described by X-ray powder diffractionin the following, obtained using Cu K-alpha radiation: D Space-Å 12.7636.389 3.194 13.244 4.259

and more preferably as: D Space-Å 12.763 6.389 3.194 13.244 4.259 12.0362.824 8.659 6.012 5.397 3.447

Also, Form II is further identified as: D Space-Å Relative Intensity12.763 Strong 6.389 Medium 3.194 Weak 13.244 Weak 4.259 Weak 12.036 Weak2.824 Weak 8.659 Weak 6.012 Weak 5.397 Weak 3.447 Weak

Further, Form II may be identified as: D Space-Å Relative Intensity (%)12.763 100.0 6.389 35.7 3.194 22.2 13.244 18.0 4.259 13.8 12.036 13.82.824 9.5 8.659 8.3 6.012 7.2 5.397 6.9 3.447 6.5

Form II may also be identified as in Table 1: TABLE 1 Relative RelativeIntensity 2 Theta Angle (°) D Space-Å Intensity (%) 6.920 12.763 Strong100.0 13.850 6.389 Medium 35.7 27.908 3.194 Weak 22.2 6.669 13.244 Weak18.0 20.838 4.259 Weak 13.8 7.339 12.036 Weak 13.8 31.660 2.824 Weak 9.510.208 8.659 Weak 8.3 14.722 6.012 Weak 7.2 16.413 5.397 Weak 6.9 25.8293.447 Weak 6.5

Form II can be used as a pharmaceutical, optionally together withpharmaceutically acceptable carriers and/or excipients. Furthermore, itcan be used for the production of other polymorphs or pseudopolymorphsof(−)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8-[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-one.

Form II is hygroscopic. It can be used in water free form or in a formwith a certain water content. The use in a form, which is essentiallyfree from water is preferred.

Another subject of the instant invention is a process for the productionof Form II of(−)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8-[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-one.Steps of the production process of Form II of(−)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8-[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-oneare

-   -   a) dissolving a sufficient amount of        (−)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8-[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-one        hydrochloride in a sufficient amount of ethanol thus forming a        mixture,    -   b) heating the mixture to about 50 to about 80° C.;    -   c) optionally filtering off undissolved material from the        mixture thus forming a solution    -   d) concentrating the solution until about 50 to about 90% of the        volatiles are removed,    -   e) cooling the solution, for example, to about 0 to 10° C. and        optionally isolating        (−)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8-[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-one        hydrochloride crystals thus obtained; and    -   f) optionally drying the crystals.

A “sufficient amount” of(−)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8-[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-onehydrochloride is that amount sufficient to be dissolved and heatedaccording to the steps of the invention to form enough crystals to berecovered. Likewise, a “sufficient amount” of ethanol is that amountsufficient to dissolve at least a portion of the(−)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8-[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-onehydrochloride added thereto in order to dissolve a portion thereof.These amounts can be experimentally determined.

The “volatiles” are those agents which may be evaporated during heatingsuch as ethanol and/or water.

The present invention also includes a pharmaceutical compositioncomprising a therapeutically effective amount of Form II and apharmaceutically acceptable carrier.

A “pharmaceutically acceptable carrier” is an agent which is non-toxic,does not interfere with the therapeutic profile of Form II and isappropriate to the method of administration. Form II is preferablyadministered by the intravenous route over an appropriate period of timefor cancer chemotherapy. Preferably, Form II is mixed with one or morepharmaceutically acceptable carriers. For example, Form II may be mixedwith iso-osmotic and pH controlled liquids such as water, dextrose/wateror saline/water for injection intravenously into the patient.

A “therapeutically effective amount” of Form II will vary with theindividual, concomitant therapy, the disease, and other variablefactors. Typically, this amount will be about 0.001 mg/kg to 100 mg/kgper day.

Form II is useful as a protein kinase inhibitor and cyclin dependentkinase inhibitor, and is useful in the treatment for various forms ofcancer.

Synthesis

In step a) of the said production process one part of(−)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8-[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-oneis dissolved in 10 to 30, preferably 15 to 25 in particular 19 to 21parts of ethanol. Preferably, ethanol which is essentially free fromwater is used.(−)-cis-2-(2-Chlorophenyl)-5,7-dihydroxy-8-[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-onecan be obtained as disclosed in U.S. Pat. No. 5,284,856; preferably,(−)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8-[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-oneis produced as outlined in Example 1 below.

The heating of the obtained mixture is carried out for preferably aboutone hour to 50 to 80, preferably 60 to 80, and in particular 70 to 79°C. If solid substance is observed in the solution, it can be filteredoff, preferably while the solution is still hot.

The obtained solution is concentrated by methods known to a personskilled in the art, preferably by distillation under atmospheric orunder reduced pressure. Concentration is carried out until 50 to 90%,preferably 55 to 85%, in particular 60 to 80% of the volatiles have beenremoved.

The remaining suspension is subsequently cooled, preferably to about 0to 10° C. and the obtained crystals are removed from the suspension,preferably by filtration.

The obtained crystals can be dried, preferably under reduced pressure.

EXAMPLE 1 Synthesis of Form II

A reactor is charged under nitrogen atmosphere with(−)-cis-1-methyl-4R-(2,4,6-trimethoxyphenyl)-3S-piperidinol) and aceticanhydride. Boron trifluoride etherate is added at a constant rate whilestirring and cooling the resulting solution to 8-20° C. After theaddition is complete the resulting mixture is stirred at 20-30° C. for3-5 hours. The reaction mixture is cooled to 8-12° C. and ice-water isadded while stirring followed by addition of aqueous sodium hydroxideuntil pH 10-11 is attained. The mixture is extracted with ethyl acetate.The ethyl acetate extracts are pooled and concentrated under vacuum. Theresidue is taken up in methanol and water. Then sodium hydroxide (about50% aqueous solution) is added. The reaction mixture is stirred at20-30° C. for 2-3 hours. The mixture is evaporated under reducedpressure at ≦80° C. The residue is cooled to 15-20° C. and brought to pH8.5-9.5 using concentrated hydrochloric acid. A solid precipitates,which is collected by filtration washed with demineralized water anddried under reduced pressure to give(−)-cis-1-methyl-4-(3-acetyl-4,6-dimethoxy-2-hydroxy)phenyl-3-piperidinol.

(−)-cis-1-Methyl-4-(3-acetyl-4,6-dimethoxy-2-hydroxy)phenyl-3-piperidinolis then added portionwise to a stirred suspension of potassium tert.butoxide in dry N,N-dimethylforamide at such a rate that the temperaturedoes not exceed 20° C. After the addition is complete the resultingmixture is stirred for one hour at ≦30° C. Methyl 2-chlorobenzoate isadded at such a rate, that the temperature does not exceed 30° C. Theresulting mixture is stirred at 20-30° C. for 4-6 hours. Demineralizedwater is added, followed by concentrated hydrochloric acid until the pHof the mixture reaches 6-8. The mixture is extracted two times usingchloroform. The chloroform extracts are pooled together and concentratedunder reduced pressure.

After cooling the remaining oil to ≦40° C, concentrated hydrochloricacid is added. The mixture is then stirred at ≦40° C. for ≦2 hours orovernight if necessary. After cooling the reaction mixture to 15-30° C.,water and chloroform are added. The resulting mixture is basified to pH8.5-10.5 using sodium hydroxide solution (50%). The phases areseparated. The aqueous layer is then extracted with chloroform. Thecombined organic extracts are evaporated under reduced pressure to yield(−)-cis-2-(2-chlorophenyl)-5,7-dimethoxy-8-[4R-(3S-hydroxy-1-methyl)-piperidinyl]-4H-1-benzopyran-4-oneas an oil, which is directly used in the next step without purification.

To(−)-cis-2-(2-chlorophenyl)-5,7-dimethoxy-8-[4R-(3S-hydroxy-1-methyl)-piperidinyl]-4H-1-benzopyran-4-one,quinoline and pyridine hydrochloride are added. The resulting mixture isheated to 160-190° C. while stirring. Stirring is continued whilemaintaining the temperature at 160-190° C. for 2 hours. After coolingthe reaction mixture to 90-110° C. water is added. The resulting mixtureis basified to pH 7.5-8.5 using saturated sodium carbonate solution, andextracted twice with a mixture of ethanol and chloroform. The combinedextracts are evaporated to dryness to obtain(+)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8-[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-onecrude as a brown gum, which is purified as follows.

To(+)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8-[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-onecrude, acetone is added. The resulting mixture is stirred at 55-60° C.for 30-60 minutes, then cooled to 15-20° C. and stirred for another 1-2hours. The precipitated solid is isolated by filtration, washed twicewith acetone and dried under reduced pressure to give(+)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8-[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-onein a purified form.

The free base from the previous step is suspended in ethanol andacidified using concentrated hydrochloric acid at such a rate that thetemperature does not exceed 30° C. During this process initially all ofthe solid dissolves and then the hydrochloride precipitates. Thesuspension is cooled to 0-10° C. and stirred for 1 hour whilemaintaining the temperature. The crystals are isolated by filtration andwashed with cold ethanol to yield(−)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8-[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-onehydrochloride, crude.

To(−)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8-[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-onehydrochloride, crude, ethanol is added. The resulting mixture is heatedto 70-79° C., stirred for 1 hour while maintaining the temperature andthen filtered while still hot. The filter cake is rinsed with hotethanol. The filtrate is concentrated by atmospheric distillation, untilabout 50% to about 90% of the volatiles have been removed. The remainingsuspension is then cooled to 0-10° C. while isolated by filtration anddried under reduced pressure to give the ethanol solvate of(−)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8-[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-onehydrochloride, purified as a yellow solid.

Flavopiridol is useful in treating a number of conditions or diseasesthat benefit from inhibition of protein kinases, and more particularlycyclin dependent kinases as previously described herein. Flavopiridol isexpected to be useful in treating a broad range of cancers including,for example, leukemia, mesothelioma and cancers of the lung (large cell,small, cell and non-small cell), colorectal, breast, ovarian, prostate,melanoma, renal, uterine body and central nervous system.

All articles and patents cited herein are hereby incorporated herein byreference.

1. A method for treating a cancer in a patient comprising administeringto said patient a therapeutically effective amount of anhydrous Form IIof(−)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8-[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-onehydrochloride ethanol solvate having an X-ray powder diffractionpattern, D Space-Å 12.763 6.389 3.194 13.244 4.259

expressed in terms of D-spacing wherein the cancer is selected from thegroup consisting of leukemia, mesothelioma, lung cancer, colorectalcancer, breast cancer, ovarian cancer, prostate cancer, melanoma, cancerof the uterine body and cancer of the central nervous system.
 2. Amethod for treating a cancer in a patient comprising administering tosaid patient a therapeutically effective amount of anhydrous Form II of(−)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8-[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-onehydrochloride ethanol solvate having an X-ray powder diffractionpattern, D Space-Å Relative Intensity 12.763 Strong 6.389 Medium 3.194Weak 13.244 Weak 4.259 Weak 12.036 Weak 2.824 Weak 8.659 Weak 6.012 Weak5.397 Weak 3.447 Weak

expressed in terms of D-spacing and relative intensity wherein thecancer is selected from the group consisting of leukemia, mesothelioma,lung cancer, colorectal cancer, breast cancer, ovarian cancer, prostatecancer, melanoma, cancer of the uterine body and cancer of the centralnervous system.
 3. A method for treating a cancer in a patientcomprising administering to said patient a therapeutically effectiveamount of anhydrous Form II of(−)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8-[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-onehydrochloride ethanol solvate having an X-ray powder diffractionpattern, Relative Relative Intensity 2 Theta Angle (°) D Space-ÅIntensity (%) 6.920 12.763 Strong 100.0 13.850 6.389 Medium 35.7 27.9083.194 Weak 22.2 6.669 13.244 Weak 18.0 20.838 4.259 Weak 13.8 7.33912.036 Weak 13.8 31.660 2.824 Weak 9.5 10.208 8.659 Weak 8.3 14.7226.012 Weak 7.2 16.413 5.397 Weak 6.9 25.829 3.447 Weak 6.5

expressed in terms of 2 theta angle, D-spacing, relative intensity and %relative intensity wherein the cancer is selected from the groupconsisting of leukemia, mesothelioma, lung cancer, colorectal cancer,breast cancer, ovarian cancer, prostate cancer, melanoma, cancer of theuterine body and cancer of the central nervous system.